Literature DB >> 2196342

Cerebrotendinous xanthomatosis: clinical, electrophysiological and nerve biopsy findings, and response to treatment with chenodeoxycholic acid.

M Donaghy1, R H King, R O McKeran, M S Schwartz, P K Thomas.   

Abstract

A 30-year-old patient with cerebrotendinous xanthomatosis was studied over a 6-year period. The clinical manifestations were cataracts, intellectual deterioration, ataxia, palatal and pharyngeal myoclonus, corticospinal tract damage and an electrophysiologically demonstrated sensorimotor peripheral neuropathy. Peripheral motor and sensory nerve conduction velocity was slowed. Sural nerve biopsy revealed reduced densities of both myelinated and unmyelinated axons and teased fibres showed evidence of axonal regeneration and some remyelination. The loss of myelinated nerve fibres particularly affected those of larger diameter, thus contributing to the slowing of nerve conduction. Chenodeoxycholic acid treatment for two separate periods of 10 and 6 months each increased nerve conduction velocity. This electrophysiological improvement was not matched by detectable clinical neurological improvement.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2196342     DOI: 10.1007/bf00314598

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  17 in total

1.  Identification of pentahydroxy bile alcohols in cerebrotendinous xanthomatosis: characterization of 5beta-cholestane-3alpha, 7alpha, 12alpha, 24xi, 25-pentol and 5beta-cholestane-3alpha, 7alpha, 12alpha, 23xi, 25-pentol.

Authors:  S Shefer; B Dayal; G S Tint; G Salen; E H Mosbach
Journal:  J Lipid Res       Date:  1975-07       Impact factor: 5.922

2.  The use of PIPES buffer in the fixation of mammalian and marine tissues for electron microscopy.

Authors:  P S Baur; T R Stacey
Journal:  J Microsc       Date:  1977-04       Impact factor: 1.758

3.  Basic two-dye stains for epoxy-embedded 0.3-1 sections.

Authors:  J Sievers
Journal:  Stain Technol       Date:  1971-07

4.  Cerebrotendinous xanthomatosis: in vivo labeling of cerebral sterols and sterol esters.

Authors:  D Gardner-Medwin; Y Kishimoto; B M Derby; H W Moser
Journal:  Trans Am Neurol Assoc       Date:  1971

5.  Cholestanolosis (cerebrotendinous xanthomatosis). A follow-up study on the original family.

Authors:  M Philippart; L Van Bogaert
Journal:  Arch Neurol       Date:  1969-12

6.  Increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid of patients with cerebrotendinous xanthomatosis. Effect of chenodeoxycholic acid.

Authors:  G Salen; V Berginer; V Shore; I Horak; E Horak; G S Tint; S Shefer
Journal:  N Engl J Med       Date:  1987-05-14       Impact factor: 91.245

7.  Diagnosis of cerebrotendinous xanthomatosis (CTX) and effect of chenodeoxycholic acid therapy by analysis of urine using capillary gas chromatography.

Authors:  B G Wolthers; M Volmer; J van der Molen; B J Koopman; A E de Jager; R J Waterreus
Journal:  Clin Chim Acta       Date:  1983-06-30       Impact factor: 3.786

8.  Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid.

Authors:  V M Berginer; G Salen; S Shefer
Journal:  N Engl J Med       Date:  1984-12-27       Impact factor: 91.245

9.  Cerebrotendinous xanthomatosis: a defect in mitochondrial 26-hydroxylation required for normal biosynthesis of cholic acid.

Authors:  H Oftebro; I Björkhem; S Skrede; A Schreiner; J I Pederson
Journal:  J Clin Invest       Date:  1980-06       Impact factor: 14.808

10.  Qualitative and quantitative morphology of human sural nerve at different ages.

Authors:  J M Jacobs; S Love
Journal:  Brain       Date:  1985-12       Impact factor: 13.501

View more
  6 in total

1.  Polyneuropathy in cerebrotendinous xanthomatosis and response to treatment with chenodeoxycholic acid.

Authors:  F Ginanneschi; A Mignarri; M Mondelli; G N Gallus; M Del Puppo; S Giorgi; A Federico; A Rossi; M T Dotti
Journal:  J Neurol       Date:  2012-08-10       Impact factor: 4.849

2.  Electrophysiological studies in cerebrotendinous xanthomatosis.

Authors:  Y Tokimura; M Kuriyama; K Arimura; J Fujiyama; M Osame
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-01       Impact factor: 10.154

3.  The neuropathology of cerebrotendinous xanthomatosis revisited: a case report and review of the literature.

Authors:  D Soffer; D Benharroch; V Berginer
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

4.  Neuromuscular abnormality and autonomic dysfunction in patients with cerebrotendinous xanthomatosis.

Authors:  Shu-Fang Chen; Nai-Wen Tsai; Chung-Chih Chang; Cheng-Hsien Lu; Chi-Ren Huang; Yao-Chung Chuang; Wen-Neng Chang
Journal:  BMC Neurol       Date:  2011-05-31       Impact factor: 2.474

Review 5.  Psychiatric manifestations in cerebrotendinous xanthomatosis.

Authors:  M J Fraidakis
Journal:  Transl Psychiatry       Date:  2013-09-03       Impact factor: 6.222

6.  Cerebrotendinous xanthomatosis with peripheral neuropathy: a clinical and neurophysiological study in Chinese population.

Authors:  Shu Zhang; Wei Li; Rui Zheng; Bing Zhao; Yongqing Zhang; Dandan Zhao; Cuiping Zhao; Chuanzhu Yan; Yuying Zhao
Journal:  Ann Transl Med       Date:  2020-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.